Results of correction of immune dysfunction in chronic cerebral ischemia
Perm Medical Journal · 07.11.2026 · 43 (5) · 72-83
DOI: 10.17816/pmj43572-83 ↗Kurz gefasst
Fachartikel in der Zeitschrift Perm Medical Journal, online erschienen am 07.11.2026. Verfasst von M. M. Abdurakhmanov und 4 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
To analyze the dynamics of neurological symptoms and cytokine levels following combination therapy in patients with chronic cerebral ischemia. Materials and methods. The randomized study included 106 patients with chronic cerebral ischemia treated in the Department of Neurology of the Bukhara Branch of the Republican Scientific Center for Emergency Medical Care in 2023-2025. All patients underwent a comprehensive set of clinical, instrumental, immunological and laboratory examinations.
Results
The inclusion of azoximer bromide in the complex therapy, compared with the use of vinpocetine and Corvitin, normalized not only the concentration of IL-1β (5.2 ± 0.3 pg/mL) to the level of the healthy donor control group (5.3 ± 0.6 pg/mL), but also the concentration of the remaining studied proinflammatory cytokines TNFα, IL-8 and IL-17, reducing them 3.0 ± 0.2 pg/mL, 2.0 ± 0.1 pg/mL, and 9.0 ± 0.3 pg/mL, respectively, which corresponded to the normal parameters of TNFα, IL-8 and IL-17 in the group of healthy donors (2.9 ± 1.1 pg/mL, 1.9 ± 0.4 pg/mL and 8.5 ± 0.4 pg/mL). The results of the study revealed that the combined use of Cavinton, Corvitin, and Azoximer bromide led to more favorable neurological dynamics, as the use of this treatment regimen resulted in a more pronounced correction towards the values of the healthy donor group in terms of the sum of subjective disorders, neurological symptoms, and cognitive impairments on the Global Deterioration Scale (GDS) (respectively, up to 0.86 ± 0.3; 1.18 ± 0.3, and 1.38 ± 0.8). Cognitive impairment on the Montreal Cognitive Assessment (MoCA) reached 24.35 ± 1.3 points, which is statistically higher than the scores of the group using vinpocetine and Corvitine (22.53 ± 0.81) and significantly closer to the scores of the group of healthy donors (27.1 ± 0.8).
Conclusions
The involvement of cytokine shifts in atherosclerotic cerebral vascular lesions in the formation and development of chronic cerebral ischemia is substantiated. The positive results of using azoximer bromide are primarily due to its significant immunomodulatory effect on immunocompetent cells, modulating their activity depending on pre-treatment parameters.
Zitieren
APA
Abdurakhmanov, M. M., Eshonov, O. S., Olimov, J. N., Rajabova, Z. S., & Abdurakhmanov, Z. M. (2026). Results of correction of immune dysfunction in chronic cerebral ischemia. Perm Medical Journal, 43(5), 72-83. https://doi.org/10.17816/pmj43572-83
Vancouver
Abdurakhmanov MM, Eshonov OS, Olimov JN, Rajabova ZS, Abdurakhmanov ZM. Results of correction of immune dysfunction in chronic cerebral ischemia. Perm Medical Journal. 2026;43(5):72-83. doi:10.17816/pmj43572-83
BibTeX
@article{Abdurakhmanov2026,
author = {Abdurakhmanov, M. M. and Eshonov, O. Sh. and Olimov, J. N. and Rajabova, Z. S. and Abdurakhmanov, Z. M.},
title = {Results of correction of immune dysfunction in chronic cerebral ischemia},
journal = {Perm Medical Journal},
year = {2026},
volume = {43},
number = {5},
pages = {72--83},
doi = {10.17816/pmj43572-83}
}
EUVIMED